Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × larotrectinib × Tumor-Agnostic × Clear all

Phase

Status

Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3 CNS 3 Sarcoma 2 Myeloid 2 Genitourinary 2 Gastrointestinal 2 Tumor-Agnostic 1 Plasma cell 1

Conditions

Interventions

pembrolizumab 20 Magnetic Resonance Spectroscopy 8 Specimen Handling 7 Nivolumab 7 Bevacizumab 7 Paclitaxel 6 Biopsy 6 Ipilimumab 5 Cyclophosphamide 5 avelumab 4 atezolizumab 4 Oxaliplatin 4 olaparib 3 niraparib 3 cemiplimab 3 X-Rays 3 Surveys and Questionnaires 3 Radiotherapy 3 Practice Guidelines as Topic 3 Leucovorin 3 Irinotecan 3 Fluorouracil 3 trastuzumab deruxtecan 2 trametinib 2 temsirolimus 2 spartalizumab 2 sargramostim 2 osimertinib 2 lenvatinib 2 fludarabine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02637687 2025-06-22

SCOUT

Bayer

Phase 1/2 Active not recruiting

154 enrolled 3 FDA

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡